-
Abstract Number: 2341
Influence of Patient Baseline Characteristics on Zasocitinib (TAK-279) Efficacy, a Selective Oral Tyrosine Kinase 2 Inhibitor: A Randomized Phase 2b Trial in Psoriatic Arthritis
-
Abstract Number: 2342
Guselkumab Shows Similar Domain-Specific Efficacy in Females and Males with Active Psoriatic Arthritis: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
-
Abstract Number: 2343
Temporal Trends in and Associations with NSAID Prescription in Adult and Pediatric Patients with IBD
-
Abstract Number: 2344
Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-year Final Results of a Prospective Real-world Study
-
Abstract Number: 2345
Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis
-
Abstract Number: 2346
Treatment Effect on Predictors of Ankylosis in Axial Spondyloarthritis
-
Abstract Number: 2347
Drug Survival in Spondyloarthritis: Anti-IL17 Outperforms Anti-TNF in First Biologic Treatment
-
Abstract Number: 2348
Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
-
Abstract Number: 2349
Predictive Potential of Serum Metabolites Associated with Treatment Response to Interleukin -17 Inhibitors in Patients with PsA
-
Abstract Number: 2350
Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data from 1,202 European Patients with Psoriatic Arthritis
-
Abstract Number: 2351
Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials
-
Abstract Number: 2352
Bimekizumab Treatment Was Efficacious to 2 Years Regardless of Duration of axSpA Symptoms: Results from Two Phase 3 Studies
-
Abstract Number: 2353
Effects of Guselkumab on cDAPSA Disease Activity State and Its Association with Long-Term Radiographic Progression in a Cohort of Patients with Moderately-Highly Active Psoriatic Arthritis: Post Hoc Analyses of Phase 3 Randomized Controlled Studies
-
Abstract Number: 2354
Predictors of Clinical Response to Intravenous Secukinumab Among Patients with PsA: A Post Hoc Analysis of a Phase 3 Trial
-
Abstract Number: 2355
Efficacy of Risankizumab Across Distinct PsA Phenotypes Identified with Machine Learning Analytics Using Data from Biologic DMARD-Naive Patients in Two Phase 3 Clinical Trials
- « Previous Page
- 1
- …
- 156
- 157
- 158
- 159
- 160
- …
- 181
- Next Page »